FY2025 EPS Forecast for TG Therapeutics Reduced by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biopharmaceutical company will earn $0.58 per share for the year, down from their prior forecast of $1.08. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share.

A number of other equities research analysts have also recently issued reports on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Stock Down 0.6 %

TGTX traded down $0.22 on Thursday, hitting $33.64. 2,237,034 shares of the company were exchanged, compared to its average volume of 3,022,129. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock's fifty day moving average is $38.90 and its 200-day moving average is $33.63. The company has a market cap of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21. TG Therapeutics has a 12 month low of $15.16 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company's quarterly revenue was up 90.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.07) earnings per share.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after buying an additional 209,190 shares during the period. Soleus Capital Management L.P. lifted its position in TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock worth $80,705,000 after acquiring an additional 146,702 shares during the last quarter. Clearbridge Investments LLC bought a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $55,237,000. Northern Trust Corp grew its position in shares of TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after purchasing an additional 120,785 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after purchasing an additional 84,904 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.